The FDA has given Breakthrough Device Designation to CorFlow so that it expedites clinical development and regulatory review of CoFI System, said the company.
Biogen is seeking approval of an experimental Alzheimer's drug that previously failed in improving conditions of people suffering from the neurodegenerative disease.